Protalix Biotherapeutics (De) (PLX) closed at $2.48 on October 26, 2026, down 2.7% from the previous close, on volume of 393,003 shares (30-day average 830,698).
Data as of October 26, 2026.
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference
PRNewswire (Mon, 26-Oct 6:50 AM ET)
Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences
PRNewswire (Tue, 8-Sep 6:45 AM ET)
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results
PRNewswire (Wed, 12-Aug 6:50 AM ET)
PRNewswire (Wed, 5-Aug 6:50 AM ET)
PLX Profit Swing Driven by $25M Milestone and Record Net Income in Q1 2026
Market Chameleon (Wed, 13-May 7:23 AM ET)
Market Chameleon (Mon, 2-Feb 6:09 AM ET)
Market Chameleon (Fri, 30-Jan 6:09 AM ET)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Protalix Biotherapeutics (De) trades on the AMEX stock market under the symbol PLX.
As of October 27, 2026, PLX stock price climbed to $2.50 with 179,611 million shares trading.
PLX has a beta of 1.22, meaning it tends to be more sensitive to market movements. PLX has a correlation of 0.07 to the broad based SPY ETF.
PLX has a market cap of $201.43 million. This is considered a Small Cap stock.
Last quarter Protalix Biotherapeutics (De) reported $20 million in Revenue and $.05 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.06.
In the last 3 years, PLX traded as high as $3.19 and as low as $.82.
The top ETF exchange traded funds that PLX belongs to (by Net Assets): IWM, IWO, VTWO, DFAS, IWC.
PLX has underperformed the market in the last year with a price return of +5.9% while the SPY ETF gained +14.7%. However, in the short term, PLX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +5.5% vs +4.4% return in SPY. But in the last 2 weeks, PLX shares have been beat by the market, returning -10.1% compared to an SPY return of -1.1%.
PLX support price is $2.42 and resistance is $2.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PLX shares will trade within this expected range on the day.
